Neuronetics, Inc.
Neuronetics, Inc. develops and commercializes NeuroStar Advanced Therapy System, a non-invasive medical device used in psychiatric care, along with recurring treatment-session access codes and related services. The company is based in the United States and sells primarily to psychiatrists and psychiatric practices, with a small international distribution footprint.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCapital equipment sales, rentals, upgrades, and related hardware for the NeuroStar platform.
Recurring access codes and treatment-session revenue used with the NeuroStar system.
Revenue from treatments performed in company-operated or affiliated clinic settings.
Service, repair, research collaboration, and extended warranty revenue.
Products
Reported · share of revenue- Services58.3 %
- Products41.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Neuronetics sells to psychiatrists, group psychiatric practices, and treatment centers that use NeuroStar to treat patients with major depressive disorder. Its revenue also depends on third-party payors, including Medicare, managed care plans, and commercial insurers, because patient reimbursement supports treatment adoption and utilization.
Buy NeuroStar systems and treatment-session access to treat MDD patients in-office and generate recurring patient revenue.
Operate treatment sites and earn clinic revenue from performed sessions and patient fees.
Medicare, managed care, and commercial insurers reimburse treatments and influence utilization.
Purchase and distribute products in select non-U.S. markets.
Strategy
Neuronetics is focused on expanding adoption of NeuroStar through direct sales coverage, customer support, and clinical evidence that supports additional indications. It also emphasizes growing recurring revenue from treatment sessions and clinic operations, while relying on outsourced manufacturing and distributor channels for parts of its operating model.
More systems in the field and higher session volume increase recurring revenue opportunities.
Broader clinical use can expand the addressable market and support adoption.
Clinic operations add a direct patient-fee stream and deepen market penetration.
Geography
The business is overwhelmingly U.S.-centric, with the United States accounting for 98% of revenue in the nine months ended September 30, 2025. International sales are limited and are handled through independent distributors in a few select markets outside the U.S.
Risks
Neuronetics depends on reimbursement, physician adoption, and patient willingness to pursue treatment, so demand can be sensitive to payor policy and macro conditions. The company also faces execution risk from outsourced manufacturing, product concentration around NeuroStar, and financial covenant/liquidity pressure associated with its capital structure.
- Reimbursement and payor policy riskImpact: HighLikelihood: High
Clinic and treatment-session demand depend on Medicare, managed care, and commercial coverage.
Exposure: U.S. psychiatric treatment reimbursement
- Liquidity and covenant riskImpact: HighLikelihood: High
Borrowings under the Perceptive Facility include revenue and liquidity covenants.
Exposure: Debt compliance and financing flexibility
- Manufacturing and supply chain riskImpact: HighLikelihood: Low
Components are produced by third-party contract manufacturers and assembled through outsourced partners.
Exposure - Product concentration riskImpact: High
The business is centered on NeuroStar and related treatment-session revenue.
Exposure: Single-platform dependence
- Macroeconomic demand sensitivityImpact: MediumLikelihood: High
Patients may delay or forego medical services during weaker economic conditions.
Exposure: Consumer and provider spending on psychiatric care
Accounting
Judgemental itemsRevenue is recognized using expected-value estimates for contractual allowances and discounts.
Impact: Can materially affect reported revenue and receivables
Payor fee schedules and concessions can change the amount ultimately recognized.
Impact: Creates estimation uncertainty in clinic revenue
System sales, treatment sessions, clinic revenue, and other services are recognized differently.
Impact: Affects revenue mix and comparability across periods
Extended warranty and repair obligations may require deferral or accruals.
Impact: Influences deferred revenue and service-cost estimates
Similar listed companies
Publicly listed companies with a comparable business focus.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Last updated: 24/09/2026